ASH 2023 | Update of the ADMIRAL trial: gilteritinib vs salvage chemotherapy prior to HSCT in FLT-3 mutated AML

Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, discusses longer-term data from the ADMIRAL study (NCT02421939) looking at the survival and relapse rates of patients who underwent hematopoietic stem cell transplantation (HSCT) in the study. ADMIRAL was a global phase III trial in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia (AML) in which participants were randomized to receive gilteritinib or preselected high- or low-intensity salvage chemotherapy. This follow-up showed similar post-transplantation survival outcomes in the two study arms. However, the higher remission rates observed with gilteritinib allowed for progression of patients to HSCT. Therefore, this study support the use of gilteritinib as a bridge to HSCT in place of chemotherapy in transplantation-eligible patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.